文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

普利特韦与伐昔洛韦对频繁复发患者生殖器HSV-2排毒影响的比较:一项随机临床试验

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2016-01-01

这项2期随机双盲交叉试验在美国4个城市的临床研究中心比较每日口服普利特韦100 mg与伐昔洛韦500 mg对生殖器HSV-2排毒的抑制作用,计划样本量98名成人,因FDA临床暂停而提前终止,91名参与者被随机分组。意向性分析显示普利特韦组HSV检出拭子比例2.4%(173/7276)低于伐昔洛韦组5.3%(392/7453),生殖器病变天数比例1.9% vs 3.9%,但HSV阳性拭子中病毒量和排毒发作频率两组无显著差异。

要点

  • 普利特韦组HSV检出拭子比例为2.4%(173/7276),伐昔洛韦组为5.3%(392/7453),RR 0.42(95%CI 0.21-0.82;P=0.01)。
  • 生殖器病变天数比例普利特韦组1.9% vs 伐昔洛韦组3.9%(RR 0.40;95%CI 0.17-0.96;P=0.04)。
  • HSV阳性拭子平均病毒量普利特韦组3.2 log10 copies/mL vs 伐昔洛韦组3.7 log10 copies/mL(差值-0.1;95%CI -0.6至0.5;P=0.83),无显著差异。

核心结论

  • 在频繁复发性生殖器HSV-2成人中,与伐昔洛韦相比,使用普利特韦在28天内HSV检出拭子比例更低。
  • 需要进一步研究评估长期疗效和安全性。

研究设计与样本

  • 2期、随机、双盲、交叉临床试验,在美国4个城市的临床研究中心开展(2012年10月至2013年7月)。
  • 比较每日口服普利特韦100 mg与伐昔洛韦500 mg;计划样本量98名成人,以检测两种研究治疗间病毒排毒减少50%。
  • 纳入标准为年生殖器HSV-2复发4至9次的健康成人;因FDA基于同期非临床毒性研究结果实施临床暂停,申办方终止研究,最终45名参与者先接受普利特韦、46名先接受伐昔洛韦。
  • 参与者先服用第一种药物28天,洗脱28天后服用第二种药物28天;整个治疗期间每天采集生殖器拭子4次,用HSV聚合酶链反应检测。

主要发现

  • 91名被随机分组参与者(中位年龄48岁;57名女性[63%])中,研究终止时56名完成了两个治疗期。
  • 意向性分析中,普利特韦治疗期间HSV检出拭子比例为2.4%(173/7276),伐昔洛韦治疗期间为5.3%(392/7453)(相对风险[RR] 0.42;95%CI 0.21至0.82;P=0.01)。
  • HSV阳性拭子中,普利特韦治疗期间平均病毒量为3.2 log10 copies/mL,伐昔洛韦治疗期间为3.7 log10 copies/mL(差值-0.1;95%CI -0.6至0.5;P=0.83)。
  • 生殖器病变存在天数比例普利特韦组为1.9%,伐昔洛韦组为3.9%(RR 0.40;95%CI 0.17-0.96;P=0.04)。
  • 排毒发作频率两组无差异,普利特韦组每人月1.3次,伐昔洛韦组每人月1.6次(RR 0.80;95%CI 0.52至1.22;P=0.29)。

关键数值与推荐

  • 主要终点为参与者内接受普利特韦期间与伐昔洛韦期间生殖器HSV排毒的对比。
  • 次要终点包括阳性拭子中HSV的量、生殖器病变频率和排毒发作频率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因FDA临床暂停而提前终止,计划样本量98名成人,最终91名被随机分组,研究终止时56名完成了两个治疗期。
  • 需要进一步研究评估长期疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current therapy of herpes infections relies on nucleoside analogues. Pritelivir is a well-tolerated novel herpes simplex virus (HSV) helicase-primase inhibitor that reduced genital shedding and lesions. OBJECTIVE: To compare the efficacy of pritelivir with valacyclovir for suppression of genital HSV-2 infection. DESIGN, SETTING, AND PARTICIPANTS: A phase 2, randomized, double-blind, crossover clinical trial at clinical research centers in 4 US cities (October 2012-July 2013) compared daily oral doses of 100 mg of pritelivir with 500 mg of valacyclovir. The planned sample size was 98 adults, allowing for detection of a 50% reduction in viral shedding between the study treatments. Healthy adults with 4 to 9 annual genital HSV-2 recurrences were eligible. 45 participants were randomized to receive pritelivir [corrected] and 46 to receive valacyclovir first when the US Food and Drug Administration placed the trial on clinical hold based on findings in a concurrent nonclinical toxicity study, and the sponsor terminated the study. INTERVENTIONS: Participants took the first drug for 28 days followed by 28 days of washout before taking the second drug for 28 days. Throughout treatment, the participants collected genital swabs 4 times daily for testing by HSV polymerase chain reaction assays. MAIN OUTCOMES AND MEASURES: The primary end point was within-participant genital HSV shedding while receiving pritelivir compared with valacyclovir. Secondary end points included the quantity of HSV in positive swabs and the frequency of genital lesions and shedding episodes. RESULTS: Of the 91 randomized participants (median age, 48 years; 57 women [63%]), 56 had completed both treatment periods at the time of the study's termination. In intent-to-treat analyses, HSV shedding was detected in 2.4% (173 of 7276 ) of swabs during pritelivir treatment compared with 5.3% (392 of 7453) during valacyclovir treatment (relative risk [RR], 0.42 [corrected]; 95% CI, 0.21 to 0.82; P = .01). In swabs with HSV, the mean quantity of HSV was 3.2 log10 copies/mL during pritelivir treatment vs 3.7 log10 copies/mL during valacyclovir treatment (difference, -0.1; 95% CI, -0.6 to 0.5; P = .83). Genital lesions were present on 1.9% of days in the pritelivir group vs 3.9% in the valacyclovir group (RR, 0.40; 95% CI, 0.17-0.96; P = .04). The frequency of shedding episodes did not differ by group, with 1.3 per person-month for pritelivir and 1.6 per person-month for valacyclovir (RR, 0.80; 95% CI, 0.52 to 1.22; P = .29). Treatment-emergent adverse events occurred in 62.3% of participants in the pritelivir group and 69.2% of participants in the valacyclovir group. CONCLUSIONS AND RELEVANCE: Among adults with frequently recurring genital HSV-2, the use of pritelivir compared with valacyclovir resulted in a lower percentage of swabs with HSV detection over 28 days. Further research is needed to assess longer-term efficacy and safety. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01658826.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Wald A, Timmler B, Magaret A, et al. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial. JAMA. 2016. PMID: 27997653. doi:10.1001/jama.2016.18189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。